Abstract:Objective To observe the efficacy and safety of bronchial arterial chemoembolization with CalliSpheres drug-eluting beads(DEB-BACE) in the treatment of refractory non-small cell lung cancer（NSCLC）. Methods From March 2016 to March 2018,21 patients with refractory NSCLC were treated with DEB-BACE.Interventional therapy:300-500 μm CalliSphere microspheres loaded with epirubicin 40-60 mg were performed with superselective microcatheter followed by arterial chemoembolization.One month after the operation,chest enhancement CT and hematological indexes were reexamined,and the tumor response was evaluated by mRECIST.The survival time the life quality and adverse reactions of patients were observed. Results Until March 2020,the follow-up period was 5-31(19.70±6.85) months.The average number of DEB-BACE was (1.78±1.02) times in 21 patients with NSCLC.After the first DEB-BACE,the objective remission rate was 90.48% and the disease control rate was 95.24%.The 3-,6-,12-,and 24-month survival rates were 100%,95.24%,71.43% and 33.33%,respectively.The median survival time was 18.5 months.After treatment,the symptoms of cough,asthma and hemoptysis basically disappeared,and the quality of life was significantly improved.There were no serious adverse events such as spinal cord injury and cerebral embolism during the perioperative period.The main adverse reactions were chest pain and fever,which were improved after symptomatic treatment. Conclusion DEB-BACE is safe and effective in the treatment of refractory NSCLC,which can prolong the survival time and improve the life quality of patients.